Dianthus Therapeutics Inc. (DNTH) - Total Liabilities
Based on the latest financial reports, Dianthus Therapeutics Inc. (DNTH) has total liabilities worth $41.25 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Dianthus Therapeutics Inc.'s assets are long-term investments to see how much of total assets are deployed in long-term investments.
Dianthus Therapeutics Inc. - Total Liabilities Trend (2016–2025)
This chart illustrates how Dianthus Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see DNTH total asset value.
Dianthus Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Dianthus Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥19.18 Billion |
|
China Coal Energy Company Limited
F:CVV
|
Germany | €169.68 Billion |
|
Fortnox AB
ST:FNOX
|
Sweden | Skr1.04 Billion |
|
Landstar System Inc
NASDAQ:LSTR
|
USA | $905.80 Million |
|
Compagnie du Cambodge
PA:CBDG
|
France | €104.90 Million |
|
Codan Ltd
AU:CDA
|
Australia | AU$354.38 Million |
|
QMMM Holdings Limited Ordinary Shares
NASDAQ:QMMM
|
USA | $71.22K |
|
Railway Signal Communication Ltd
SHG:688009
|
China | CN¥67.23 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Dianthus Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Dianthus Therapeutics Inc.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dianthus Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dianthus Therapeutics Inc. (2016–2025)
The table below shows the annual total liabilities of Dianthus Therapeutics Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $37.52 Million | +74.27% |
| 2024-12-31 | $21.53 Million | +104.38% |
| 2023-12-31 | $10.54 Million | +11.43% |
| 2022-12-31 | $9.45 Million | -45.23% |
| 2021-12-31 | $17.26 Million | -2.55% |
| 2020-12-31 | $17.71 Million | -12.83% |
| 2019-12-31 | $20.32 Million | +74.20% |
| 2018-12-31 | $11.66 Million | +181.63% |
| 2017-12-31 | $4.14 Million | +80.09% |
| 2016-12-31 | $2.30 Million | -- |
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more